A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with biologics in a real-world setting (PSO-BIO-REAL)

J. Seneschal, J.-P. Lacour, A. Bewley, M. Faurby, C. Paul, G. Pellacani, C. De Simone, L. Horne, A. Sohrt, M. Augustin, E. Hammond, K. Reich
1Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin Diseases, Saint-André Hospital, University of Bordeaux, Bordeaux, France
2Department of Dermatology, Archet 2 Hospital, University Hospital of Nice, Nice, France
3Department of Dermatology, Barts Health NHS Trust London, London, UK
4LEO Pharma A/S, Ballerup, Denmark
5Toulouse University and Larrey Hospital, Toulouse, France
6Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
7Department of Dermatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy
8AstraZeneca, Gaithersburg, MD, USA
9Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany
10Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and SkinInflammation® Center, Hamburg, Germany
*Correspondence: J. Seneschal. E-mail: julien.seneschal@chu-bordeaux.fr

Abstract
Background Anti-tumour necrosis factor (TNF) and anti-interleukin (IL)-12/23 biologics revolutionized plaque psoriasis treatment by enabling ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) in clinical trials. Modern biologics are now reported to achieve PASI 100 (complete skin clearance) in clinical trials. However, real-world evidence of skin clearance rates with biologics is limited. PSO-BIO-REAL was conducted to understand the real-world burden of plaque psoriasis.

Objective The primary objective of this observational study was to estimate the proportion of patients who achieved complete skin clearance at 6 months. Secondary objectives included maintenance of response and evaluation of complete skin clearance at 12 months.

Methods PSO-BIO-REAL was a multinational, prospective, real-world, non-interventional study of skin clearance and patient-reported outcomes (PROs) with biologics. A total of 846 patients from the United States (32%), France (28%), Italy (22%), the United Kingdom (11%) and Germany (8%) were enrolled and followed for one year. Eligible patients were aged ≥18 years with moderate-to-severe plaque psoriasis who had initiated a biologic for plaque psoriasis. Patients could be biologic-naïve or switching biologics (biologic-experienced). Assessments were made at baseline and at months 6 and 12.

Results At 6 and 12 months, 23% and 26% of patients achieved complete skin clearance, respectively. Prior to study entry, 60% were biologic-naïve. The proportion of patients achieving complete skin clearance was lower among biologic-experienced patients (20% at both months 6 and 12) compared with biologic-naïve patients (25% at month 6, 30% at month 12). The rate of complete skin clearance decreased as the number of prior biologics and baseline comorbidities increased.

Conclusion Only one in four patients achieved complete skin clearance after 6 months of treatment with biologics. The study indicates there still is an unmet need for more efficacious biologics for patients with psoriasis.

Received: 5 August 2019; Accepted: 27 March 2020
Conflicts of interest
J. Seneschal has been a consultant for AbbVie, Eli Lilly, Janssen, Novartis and Pfizer; J-P. Lacour has been a consultant for, has received grants from and/or has served as a speaker for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis and Pfizer; A. Bewley has been a consultant for and/or has received honoraria and/or investigator fees from AbbVie, Almirall, Bristol-Myers-Squibb, Celgene, Eli Lilly, Fresenius Medical Care, Galderma, Janssen, LEO Pharma, Novartis, Sanofi and UCB Pharma; C. Paul has been a consultant for and has received grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sandoz and UCB Pharma; C. De Simone has been a consultant, speaker and/or advisory board member for AbbVie, Almirall, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi and UCD Pharma; K. Reich has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermina, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Miltenyi Biotec, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB, Valeant and Xenopont; G Pellacani has been a consultant for LEO Pharma; A. Sohrt and M. Faurby are employees of LEO Pharma; E. Hammond is an employee of AstraZeneca; L. Horne was a paid consultant to AstraZeneca at the time the work was conducted; M Augustin reports no conflicts of interest.

Funding sources
The PSO-BIO-REAL study was sponsored by Amgen/AstraZeneca. This manuscript was sponsored by LEO Pharma.

Introduction
The aspirational treatment goal for all diseases is cure. The technical treatment goal is based on what drugs can realistically achieve in the majority of patients, as well as patient wants and needs. In plaque psoriasis, The Psoriasis Area and Severity Index (PASI) 75 was implemented as a technical treatment goal some years ago, because it was achievable with adalimumab, infliximab and ustekinumab in the majority of patients.1–4 Today, PASI 90 is being discussed as a new technical treatment goal, because it is now more readily achievable5 and because registry data indicate that significantly more patients who achieve PASI 90 are no longer bothered by their psoriasis symptoms, defined as a Dermatology Life Quality Index (DLQI) of 0/1, compared with patients who achieved PASI 75.6

Recently, it has been shown that high rates of efficacy – including PASI 100 – can be achieved with modern biologics, including anti-interleukin (IL)-17A (secukinumab and ixekizumab), anti-IL-17A receptor (anti-IL-17RA; brodalumab)7–10 and anti-IL-23 (guselkumab and risankizumab) therapies.11–13 Randomized controlled clinical trials have shown that achieving PASI 100, compared with having residual disease (e.g., PASI 75), is clinically meaningful and substantially reduces the physical burden of psoriasis, improves treatment satisfaction and reduces the impact on health-related quality of life (HRQoL).14–16

Clinical data on complete skin clearance of psoriasis among real-world cohorts of patients treated with biologics are limited. We identified only five multicentre observational studies with >100 patients from a literature search performed as background for this study, and reported clearance rates were highly variable, ranging from 3% to 79%.17–21

We therefore conducted the plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL) study – a multinational, prospective, observational cohort, real-world study designed to describe the usual care of patients with plaque psoriasis over a 12-month period following initiation of a biologic treatment in both biologic-naive and biologic-experienced patients.

Materials and methods
PSO-BIO-REAL was a multinational, prospective, observational study involving a cohort of patients with moderate-to-severe plaque psoriasis from the United States, France, Italy, Germany and the United Kingdom. The study design is illustrated in Fig. 1. Patients were eligible to participate if they were ≥18 years, had been diagnosed with moderate-to-severe plaque psoriasis, were either initiating a biologic for the first time (biologic-naive) or in the process of switching to another biologic (biologic-experienced). Patients were excluded if they had participated in an investigational clinical trial ≤3 months prior to the start of treatment. The first patient was enrolled 05 March 2014 and the last was enrolled 26 November 2015, with the final 12-month follow-up completed 05 January 2017. The duration of patient enrolment varied by country. Written informed consent was obtained from each patient.

Baseline observations (patient demographics, disease characteristics, comorbidities and prior treatment history) were recorded at the baseline visit, which either coincided with or occurred after the enrolment visit. The index date was defined as the date the first dose of a new biologic was given and either coincided with or occurred after the baseline visit. Study
assessments (PASI, static Physician’s Global Assessment, static Patient’s Global Assessment, Psoriasis Severity Index, DLQI, treatment satisfaction and global health status) were collected at baseline visit and at study visits scheduled 6 and 12 months after initiation of the index biologic. Data on comorbidities were recorded on the study case report form over the 6 months prior to study entry. Any new comorbidities of interest were reported (yes/no) by physicians at any patient visit during the study.

The primary objective was to estimate, in patients who were biologic-naïve or biologic-experienced, the effectiveness of biologics in moderate-to-severe plaque psoriasis, measured by the proportion of patients with complete skin clearance [PASI 100 or static PASI (sPASI) = 0] 6 months after initiation of a biologic. Secondary objectives were to determine the achievement of PASI 100 at 12 months and maintenance of PASI 100 from 6 to 12 months. An exploratory objective was to characterize the PASI response according to the number of baseline comorbidities. An additional objective, defined post hoc, was to describe complete clearance rates according to the index biologic treatment. In this analysis, the effectiveness in treatment groups with 30 or more patients was reported at baseline and assessed until end of the study or biologic treatment switch.

Data were analysed descriptively as observed. A sensitivity analysis on PASI 75, 90 and 100 rates using the non-responder imputation (NRI) method was performed. For continuous measures, mean, SD, minimum, median and maximum were used, and for ordinal data number and proportion were tabulated. In analyses by index biologics data, we report number and proportion switched at month 6 and 12, and have disregarded data after the switch to new treatment. All quantitative analyses were conducted using SAS Version 9.4.

Results
Patient disposition is summarized in Fig. 2. A total of 846 patients with moderate-to-severe plaque psoriasis were enrolled in the study, of which 60% were biologic-naïve and 40% were biologic-experienced and in the process of switching to a different biologic agent prior to study entry. A total of 197 patients discontinued the study, the majority (\( n = 136 \)) of whom were lost to follow-up. A total of 108 patients switched from their index treatment during the study, of which 51% switched due to primary failure and 15% switched due to secondary failure. Patients were recruited from the United States (32%), France (28%), Italy (22%), the United Kingdom (11%) and Germany (8%). Baseline characteristics are summarized in Table 1. The descriptive observations indicated that biologic-experienced patients tended to be slightly older than biologic-naïve patients (50 vs. 46 years), with a longer disease duration (20 vs. 17 years) and more comorbidities (26% vs. 18% had ≥3 comorbidities), including psoriatic arthritis (35% vs. 23%) (Tables 1 and 2). The initial biologic treatment (index biologic) was an anti-tumour necrosis factor agent (anti-TNF: etanercept, infliximab, adalimumab and certolizumab pegol) in 61%, an anti-IL-12/-23 agent (ustekinumab) in 30% and an anti-IL-17 agent (secukinumab) in 9% of patients. Baseline characteristics were generally similar among all treatment groups (Table 2). During the study, 23% of the patients were treated with concomitant psoriasis medication.

A total of 603 patients completed a 6-month PASI assessment; of these, 22.7% achieved complete skin clearance (24.9% of biologic-naïve patients and 19.6% of biologic-experienced patients) (Fig. 3). At month 12, 522 patients completed a PASI assessment, in whom complete skin clearance reported for 26.1%
Complete skin clearance in real-world

(30.4% of biologic-naïve patients and 19.5% of biologic-experienced patients). Achievement of PASI 75 and PASI 90 was reported for more biologic-naïve patients than for biologic-experienced patients. Among patients who achieved complete skin clearance at month 6, 72.4% maintained their responses through month 12; 13.4% of the patients who had not achieved complete skin clearance by month 6 achieved it at month 12.

An NRI method was applied to the efficacy analysis which showed that 16% of the patients achieved complete skin clearance at both month 6 and 12. PASI 75 and PASI 90 were achieved by 25% and 38% of the patients at month 6, respectively (Fig. S1).

The complete skin clearance rate for patients who continued their index biologic treatment throughout the course of the study ranged from 9.6% to 25.9% at 6 months and from 19.2% to 33.3% at 12 months, depending on the index biologic (Fig. 4a). Data for patients who switched to another biologic were excluded from this analysis after the switch. The proportion of patients who switched to another treatment during the study was 18.9% for etanercept, 15.2% for adalimumab and 6.6% for ustekinumab and secukinumab, respectively. Two biologics were not illustrated in Fig. 4a because of low patient numbers in both groups: infliximab (n = 12), for which the complete skin clearance was 16.7% and 8.3% at 6 and 12 months, respectively, and certolizumab pegol (n = 1), for which the rate was 0% at both 6 and 12 months.

The rate of complete skin clearance decreased as the number of prior biologics received increased, from 30.4% with no prior biologics to 10.0% at month 12 with ≥3 prior biologics (Fig. 4b). Generally, rate of complete skin clearance at month 6 decreased as the number of comorbidities at baseline increased: 31.7% of patients with no comorbidities at baseline achieved PASI 100 compared with 16.4% of patients who had ≥3 comorbidities at baseline (Fig. 5).

A total of 28% of the patients had concomitant psoriatic arthritis and the level of complete skin clearance for these patients was 15.6% at month 6 and 25.2% at month 12.

Table 1 Baseline characteristics of patients enrolled in PSO-BIO-REAL

| Characteristic                  | Biologic-naïve\(n = 509\) | Biologic-experienced\(n = 337\) | Index biologic\$ | Overall (\(N = 846\)) |
|---------------------------------|---------------------------|-------------------------------|----------------|----------------------|
|                                |                           |                               | Adalimumab\(n = 343\) | Etanercept\(n = 143\) | Ustekinumab\(n = 256\) | Secukinumab\(n = 76\) |
| Male, n (%)                     | 321 (63.1)                | 214 (63.5)                    | 207 (60.3)       | 98 (68.5)           | 158 (61.7)            | 52 (68.4)            | 535 (63.2)          |
| Age, years, mean (SD)           | 45.7 (14.0)               | 50.0 (12.9)                   | 46.4 (14.0)      | 49.4 (14.6)         | 46.0 (13.3)          | 50.8 (11.5)          | 59.5 (10.6)         |
| BMI, kg/m\(^2\), mean (SD)      | 28.8 (6.8)                | 30.3 (6.7)                    | 29.0 (6.7)       | 29.0 (6.7)          | 29.2 (6.8)           | 31.0 (5.7)           | 29.4 (6.8)          |
| White, n (%)                    | 473 (92.9)                | 308 (91.4)                    | 312 (91.0)       | 139 (97.2)          | 232 (90.6)           | 70 (92.1)            | 781 (92.3)          |
| PASI at baseline, mean (SD)     | 14.38 (8.5)               | 14.18 (10.5)                  | 13.9 (8.5)       | 14.0 (8.4)          | 13.8 (9.4)           | 16.6 (12.1)          | 14.30 (9.3)         |
| PASI at baseline, median        | 13.20                     | 11.30                         | 16.6             | 12.0                | 11.4                | 14.7                | 12.3               |
| DLQI at baseline, mean (SD)     | 12.9 (7.6)                | 11.6 (7.7)                    | 12.1 (7.3)       | 11.9 (7.4)          | 12.6 (7.8)           | 13.8 (8.4)           | 12.4 (7.6)          |
| Duration of psoriasis, years, mean (SD) | 17.1 (13.3)      | 20.4 (12.8)                   | 17.8 (12.9)      | 19.7 (14.7)         | 18.2 (13.1)          | 20.3 (12.7)          | 18.4 (13.2)         |
| Psoriatic arthritis, yes, n (%) | 119 (23)                  | 119 (35)                      | 96 (28.0)        | 46 (32.2)           | 67 (26.2)            | 22 (28.9)            | 238 (28)           |
| Biologic-experienced, n (%)     | 0 (0.0)                   | 337 (100.0)                   | 88 (25.7)        | 32 (22.4)           | 154 (60.2)           | 49 (64.5)            | 337 (39.8)         |

BMI, body mass index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
\(\dagger\) Subjects who were not exposed to biologic treatment prior to study enrolment.
\(\ddagger\) Two patients received certolizumab pegol and 26 patients received infliximab. Aggregated baseline characteristics for these patients have not been reported separately by index biologic because of low numbers.

Figure 2 Patient disposition. *Completed biologic at month 6 is defined as subjects from the full analysis set who received a biologic for approximately 6 months or 183 days (up until their completed month 6 visit). Completed biologic at month 12 is defined as subjects from the full analysis set who received a biologic for approximately 1 year or 365 days (up until their completed month 12 visit). †Completed month 6/12 assessment is defined as subjects who underwent a PASI assessment within the month 6/12 visit window.

JEADV 2020, 34, 2566-2573 © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
fewer types of biologics and reporting from only one country, published observational studies of fewer patients treated with multiple centres across five countries. Compared with previously patients treated with any of six different biologics enrolled in this study were lower in patients who had previously been exposed to biologics compared with those who were biologic-naive, and the rate of complete skin clearance decreased with increasing numbers of prior biologics. These observations are consistent with those seen in other real-world studies.

This study adds important evidence to the limited real-world evidence available.

In this study, approximately one in four patients with psoriasis achieved complete skin clearance after 6 months of real-world treatment with biologics. These results suggest that there remains a need for efficacious therapeutics for psoriasis. The first patient to be included in the study was enrolled in 2014 and the last in 2015; therefore, newer biologics such as brodalumab, guselkumab, ixekizumab and tildrakizumab were not included. Some of these newer therapies have shown greater efficacy than drugs such as ustekinumab and etanercept in clinical trials, and patients are more likely to achieve complete skin clearance. Therefore, real-world rates of complete clearance may have improved since this study concluded.

While PASI at baseline was similar for biologic-naive and biologic-experienced patients, rates of complete skin clearance in this study were lower in patients who had previously been exposed to biologics compared with those who were biologic-naive, and the rate of complete skin clearance decreased with increasing numbers of prior biologics. These observations are consistent with those seen in other real-world studies.

Comorbidities at baseline

| Comorbidity                  | Biologic-naive | Biologic-experienced | Overall |
|-----------------------------|----------------|----------------------|---------|
|                             | (n = 509)      | (n = 337)            | (N = 846) |
| Subjects with at least one  |                |                      |         |
| comorbidity                 | 310 (60.9)     | 231 (68.5)           | 541 (63.9) |
| Number of comorbidities at  |                |                      |         |
| baseline                    |                |                      |         |
| 0                           | 199 (39.3)     | 106 (31.7)           | 305 (36.3) |
| 1                           | 151 (29.8)     | 72 (21.6)            | 223 (26.5) |
| 2                           | 68 (13.4)      | 68 (20.4)            | 136 (16.2) |
| ≥3                          | 89 (17.6)      | 88 (26.3)            | 177 (21.0) |

Comparing to 25.2% at month 6 and 26.4% at month 12 for the patients without psoriatic arthritis.

**Discussion**

To our knowledge, PSO-BIO-REAL is the largest multinational, observational, real-world study to date assessing the level of complete skin clearance in adult patients with moderate-to-severe plaque psoriasis undergoing biologic treatment, with 846 patients treated with any of six different biologics enrolled in multiple centres across five countries. Compared with previously published observational studies of fewer patients treated with fewer types of biologics and reporting from only one country,
similar observation was made as the number of comorbidities at baseline increased. Although clearance rates are lower in these more complex patients, some patients still experience a clinical response to treatment with more biologics. Real-world studies such as this may be valuable in providing physicians with data that can guide them to further therapeutic options for these difficult-to-treat patients. Complete skin clearance rates were generally observed to be similar at months 6 and 12 for adalimumab, ustekinumab and secukinumab. In clinical trials, however, complete clearance rates for secukinumab were observed to be higher than for adalimumab, etanercept and ustekinumab. The PASI at baseline were similar across treatment arms; however, complete clearance rates for secukinumab were also higher (60.2%) compared to adalimumab and etanercept. Moreover, real-world data differ from RCTs in that it is not equally controlled and there may be underlying factors explaining the low rates of efficacy, not taken into account in this study.

In the main analysis, the rates of complete skin clearance were reported as observed. Accordingly, the effectiveness of biologics may be overestimated as patients that are lost to follow-up are not included. The rates of complete skin clearance were observed to be higher at 12 months than at 6 months which may be due to the number of patients discontinuing the study before month 12. Furthermore, a number of patients switched treatment during the study, which may have resulted in higher complete skin clearance rates per index biologic, as the patients who switched treatment might have experienced a low response on the index biologic. An NRI method was applied to the efficacy analysis which showed lower levels of complete skin clearance than the analysis reported as observed. The NRI method is a conservative approach that may underestimate efficacy, while the observed data might overestimate the efficacy.

Figure 5 PASI responses at 6 months according to number of comorbidities at baseline. Columns may not add up to 100% due to rounding. PASI, Psoriasis Area and Severity Index; PASI X, X% improvement from baseline in PASI score.
from the main analysis in this study are not directly comparable with those of randomized controlled trials (RCTs) where a non-responder imputation is commonly applied. Although NRI was applied in a sensitivity analysis, it also has limitations in terms of comparison, as patients are expected to drop out more frequently in real life than they do in a clinical trial. This will have an impact on the results when NRI is applied. This is a large, real-world study that adds important insights beyond what RCTs provide to the evidence of complete clearance among patients treated with biologics for plaque psoriasis.28

Conclusions
In this large, prospective, real-world study, the overall rate of complete skin clearance with the studied biologic treatments was low, achieved by 23% of patients at 6 months. The proportion achieving a response was smaller among patients who were switching biologics at study entry compared with those who were biologic-naive. Likewise, the proportion of patients who achieved complete skin clearance decreased as the number of baseline comorbidities increased. Finally, the present study indicates that there is an unmet need for complete skin clearance in clinical practice, which may be improved with newer biologic therapies that have shown high rates of complete skin clearance in clinical trials. More insights are needed to understand how the unmet need can be addressed.

Acknowledgements
The PSO-BIO-REAL study was sponsored by Amgen and Astrazeneca. Writing and editorial support, provided by Robyn Foster, PhD, and Ian Eustace, BSc, from Adelphi Communications, Ltd, Bollington, UK, were funded by LEO Pharma.

References
1 Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag 2008; 4: 345–351.
2 Farhi D. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. Drugs Today (Barc) 2010; 46: 259–264.
3 Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–1374.
4 Pathirana D, Ormerod AD, Saag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1–70.
5 Manalo IF, Gilbert KE, Wu JJ. Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol 2015; 14: 1086–1088.
6 Puig L, Thom H, Mollon P et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2017; 31: 213–220.
7 Blauvelt A, Reich K, Tsai T-F et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76: 60–69, e69.
8 Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318–1328.
9 Papp KA, Leonardi CL, Blauvelt A et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blind, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol 2018; 178: 674–681.
10 Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273–286.
11 Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate-to-severe psoriasis: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417.
12 Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661.
13 Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomised withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418–431.
14 Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75: 77–82.e7.
15 Takeshita J, Callis Duffin K, Shin DB et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 2014; 71: 633–641.
16 Viswanathan HN, Chau D, Milmont CE et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat 2015; 26: 235–239.
17 Armesto S, Coto-Segura P, Mayorga J et al. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: a retrospective study of 100 patients in daily practice. J Dermatol Treat 2013; 24: 49–53.
18 Carrera CG, Dapavo P, Malagoli P et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatol Treat 2018; 29: 481–486.
19 Deza G, Notario J, Lopez-Ferrer A et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553–559.
20 Galluzzo M, Talamonti M, De Simone C et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018; 18: 727–735.
21 Zweegers J, Roosenboom B, van de Kerkhof PC et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BIOCAPTURE cohort. Br J Dermatol 2017; 176: 786–793.
22 Sawyer LM, Malottki K, Sabry-Grant C et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE 2019; 14: e0220868.
23 Blauvelt A, Papp KA, Lebwohl MG et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol 2017; 77: 372–374.
24 Blauvelt A, Griffiths CE, Lebwohl M et al. Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. Br J Dermatol 2017; 177: 587–590.
25 Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–356.

JEADV 2020, 34, 2566–2573 © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology
Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Patients achieving PASI 75, PASI 90, and PASI 100 or sPASI 0 at months 6 and 12 by prior biologic use using the non-responder imputation method.